BioForce Nanosciences Holdings Inc
OTC:BFNH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioForce Nanosciences Holdings Inc
OTC:BFNH
|
US |
Balance Sheet
Balance Sheet Decomposition
BioForce Nanosciences Holdings Inc
BioForce Nanosciences Holdings Inc
Balance Sheet
BioForce Nanosciences Holdings Inc
| Dec-2006 | Dec-2007 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
4
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Net |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| PP&E Gross |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
5
N/A
|
3
-39%
|
0
-99%
|
0
+27%
|
0
+68%
|
0
+68%
|
0
-32%
|
0
-72%
|
0
-94%
|
0
-14%
|
0
+50%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
1
-23%
|
0
-98%
|
0
-10%
|
0
-58%
|
0
+119%
|
0
+3 347%
|
1
+118%
|
1
+54%
|
2
+35%
|
2
+27%
|
|
| Equity | ||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
10
|
14
|
1
|
1
|
1
|
1
|
159
|
160
|
160
|
161
|
161
|
|
| Additional Paid In Capital |
14
|
16
|
1
|
1
|
1
|
1
|
159
|
159
|
159
|
159
|
159
|
|
| Total Equity |
4
N/A
|
2
-43%
|
0
-100%
|
0
+257%
|
0
+263%
|
0
+59%
|
0
N/A
|
1
-139%
|
1
-56%
|
2
-35%
|
2
-27%
|
|
| Total Liabilities & Equity |
5
N/A
|
3
-39%
|
0
-99%
|
0
+27%
|
0
+68%
|
0
+68%
|
0
-32%
|
0
-72%
|
0
-94%
|
0
-14%
|
0
+50%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
24
|
25
|
15
|
15
|
15
|
15
|
29
|
29
|
29
|
29
|
29
|
|
| Preferred Shares Outstanding |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|